Table 3 Biologic and non-biologic medication use at the time of safety events with CTCAE grade 3 or higher
Event | CTCAE grade | CTP Arm | Current Biologic and Non-Biologic Use |
|---|---|---|---|
Acute liver failure | 5 | Biologic | anakinra |
Liver enzyme elevation | 4 | Biologic | anakinra |
MAS | 4 | Biologic | anakinra |
Injection site reaction | 3 | Biologic | anakinra |
Infection (osteomyelitis) | 3 | Biologic | canakinumab |
Liver enzyme elevation | 3 | Biologic | anakinra |
MAS | 3 | Biologic | canakinumab |
MAS | 3 | Biologic | canakinumab |
MAS | 3 | Biologic | canakinumab |
MAS | 3 | Biologic | none |
MAS | 3 | Biologic | none |
Neutropenia | 3 | Biologic | tocilizumab |
Neutropenia | 3 | Biologic | anakinra |
Protein losing enteropathy | 3 | Biologic | anakinra |
SJIA flare | 3 | Biologic | canakinumab |
SJIA flare | 3 | Biologic | anakinra, cyclosporine |